PT101061A - Composicoes farmaceuticas contendo anagolos da camptotecina e um composto de coordenacao de platina e seu uso na inibicao do crescimento de celulas tumorais - Google Patents

Composicoes farmaceuticas contendo anagolos da camptotecina e um composto de coordenacao de platina e seu uso na inibicao do crescimento de celulas tumorais

Info

Publication number
PT101061A
PT101061A PT101061A PT10106192A PT101061A PT 101061 A PT101061 A PT 101061A PT 101061 A PT101061 A PT 101061A PT 10106192 A PT10106192 A PT 10106192A PT 101061 A PT101061 A PT 101061A
Authority
PT
Portugal
Prior art keywords
cell growth
tumor cell
platinum coordination
coordination compound
anagols
Prior art date
Application number
PT101061A
Other languages
English (en)
Other versions
PT101061B (pt
Inventor
Randall Keith Johnson
Original Assignee
Smithkline Beckman Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beckman Corp filed Critical Smithkline Beckman Corp
Publication of PT101061A publication Critical patent/PT101061A/pt
Publication of PT101061B publication Critical patent/PT101061B/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Seasonings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT101061A 1991-11-15 1992-11-13 Composicoes farmaceuticas contendo anagolos da camptotecina e um composto de coordenacao de platina e seu uso na inibicao do crescimento de celulas tumorais PT101061B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79304191A 1991-11-15 1991-11-15

Publications (2)

Publication Number Publication Date
PT101061A true PT101061A (pt) 1994-06-30
PT101061B PT101061B (pt) 1999-07-30

Family

ID=25158913

Family Applications (1)

Application Number Title Priority Date Filing Date
PT101061A PT101061B (pt) 1991-11-15 1992-11-13 Composicoes farmaceuticas contendo anagolos da camptotecina e um composto de coordenacao de platina e seu uso na inibicao do crescimento de celulas tumorais

Country Status (14)

Country Link
US (1) US5633016A (pt)
EP (3) EP1393729A3 (pt)
JP (1) JPH07501079A (pt)
AT (1) ATE247471T1 (pt)
AU (1) AU671605B2 (pt)
CA (1) CA2123321C (pt)
DE (1) DE69233169T2 (pt)
DK (1) DK0612248T3 (pt)
ES (1) ES2204894T3 (pt)
MX (1) MX9206577A (pt)
NZ (1) NZ245112A (pt)
PT (1) PT101061B (pt)
WO (1) WO1993009782A1 (pt)
ZA (1) ZA928771B (pt)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552154A (en) 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
ATE247471T1 (de) * 1991-11-15 2003-09-15 Smithkline Beecham Corp Cisplatin und topotecan enthaltende zusammensetzung als antitumor.
DE69409633T2 (de) * 1993-01-15 1998-08-06 The Stehlin Foundation For Cancer Research, Houston, Tex. Transdermal behandlung von krebs mit wasserunlöslichem s-camtothecin mit geschlossenem lactoring
ES2206478T3 (es) 1994-11-11 2004-05-16 Debiopharm S.A. Composiciones carcinostaticas que contienen cis-oxaliplatino y otra u otras sustancias carcinostaticas compatibles.
US6274576B1 (en) 1995-06-27 2001-08-14 The Henry Jackson Foundation For The Advancement Of Military Medicine Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
JPH11509193A (ja) * 1995-06-27 1999-08-17 ヘンリー エム．ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディシン 細胞傷害を増強するための細胞周期動力学の動的遅延方法
GB9804013D0 (en) 1998-02-25 1998-04-22 Sanofi Sa Formulations
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
EP1044977B1 (en) * 1999-03-09 2002-05-02 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Camptothecin derivatives having antitumor activity
US7105492B2 (en) * 1999-03-09 2006-09-12 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Camptothecin derivatives having antitumor activity
CA2367692A1 (en) * 1999-03-15 2000-09-21 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
EP1754488A1 (en) 1999-05-24 2007-02-21 Introgen Therapeutics, Inc. Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6420378B1 (en) * 1999-10-15 2002-07-16 Supergen, Inc. Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
WO2001066144A2 (en) * 2000-03-08 2001-09-13 Rhode Island Hospital, A Lifespan Partner Antineoplastic combination comprising an inhibitor of angiogenesis and an inhibitor of dna topoisomerase i enzyme activity
US6545010B2 (en) * 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
US10293056B1 (en) 2000-05-24 2019-05-21 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
DE10032256C2 (de) * 2000-07-03 2003-06-05 Infineon Technologies Ag Chip-ID-Register-Anordnung
WO2002045737A2 (en) * 2000-12-07 2002-06-13 Board Of Regents, The University Of Texas System Methods of treatment involving human mda-7
US6476068B1 (en) 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
AU2003228267A1 (en) * 2002-03-05 2003-09-22 Board Of Regents, The University Of Texas System Methods of enhancing immune induction involving mda-7
KR20120002613A (ko) 2002-08-12 2012-01-06 제네렉스, 인코포레이티드 폭스바이러스 및 암과 관련된 방법 및 조성물
CN102836420B (zh) * 2003-03-03 2014-03-12 得克萨斯州大学系统董事会 包含mda-7的组合物和方法
WO2005082396A2 (en) * 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Use of mda-7 to inhibit infection by pathogenic organisms
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
AU2006211960A1 (en) * 2005-02-08 2006-08-17 Board Of Regents, The University Of Texas System Compositions and methods involving MDA-7 for the treatment of cancer
EP1888105A2 (en) * 2005-05-12 2008-02-20 Introgen Therapeutics, Inc. P53 vaccines for the treatment of cancers
WO2007006019A1 (en) * 2005-07-06 2007-01-11 University Of South Florida Materials and methods for screening, diagnosis and prognosis of conditions associated with stat protein expression
KR101772375B1 (ko) * 2005-09-07 2017-08-29 신라젠(주) Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성 및/또는 전신 파종성 암의 전신 치료법
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
WO2007092944A2 (en) * 2006-02-08 2007-08-16 Introgen Therapeutics, Inc. Compositions and methods involving gene therapy and proteasome modulation
US20110028536A1 (en) * 2006-08-18 2011-02-03 Gjerset Ruth A Methods and compositions for topoisomerase i modulated tumor suppression
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
KR20080084528A (ko) 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
US20100310661A1 (en) * 2007-07-16 2010-12-09 Poniard Pharmaceuticals, Inc. Oral formulations for picoplatin
CA2715348A1 (en) * 2008-02-08 2009-08-13 Poniard Pharmaceuticals, Inc. Use of picoplatin and bevacizumab to treat colorectal cancer
ES2848650T3 (es) 2009-09-14 2021-08-11 Sillajen Biotherapeutics Inc Terapia combinada contra el cáncer con virus vaccinia oncolítico
EP3012329B1 (en) 2010-06-18 2017-10-25 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
WO2012027224A1 (en) 2010-08-24 2012-03-01 Dana-Farber Cancer Institute, Inc. Methods for predicting anti-cancer response
AU2012204467B2 (en) 2011-01-04 2016-08-18 Sillajen, Inc. Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
JP6117194B2 (ja) 2011-06-17 2017-04-19 ミリアド・ジェネティックス・インコーポレイテッド アレル不均衡を評価するための方法および材料
BR112014015152A2 (pt) 2011-12-21 2017-07-04 Myriad Genetics Inc métodos e materiais para a avaliação da perda de heterozigosidade
WO2013094581A1 (ja) * 2011-12-21 2013-06-27 株式会社ヤクルト本社 新規なカンプトテシン誘導体
CA2864481C (en) 2012-02-23 2020-07-14 Dana-Farber Cancer Institute, Inc. Methods for predicting anti-cancer response
WO2013182645A1 (en) 2012-06-07 2013-12-12 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
US10308986B2 (en) 2013-03-14 2019-06-04 Children's Medical Center Corporation Cancer diagnosis, treatment selection and treatment
AU2014248007B2 (en) 2013-04-05 2020-03-26 Myriad Genetics, Inc. Methods and materials for assessing homologous recombination deficiency
WO2015077753A1 (en) * 2013-11-25 2015-05-28 The University Of Toledo Inhibitors of ercc1-xpf and methods of using the same
WO2015086473A1 (en) 2013-12-09 2015-06-18 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
CA2958801A1 (en) 2014-08-15 2016-02-18 Myriad Genetics, Inc. Methods and materials for assessing homologous recombination deficiency
EP4141127B1 (en) 2021-08-30 2024-10-09 Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln Method for assessing homologous recombination deficiency in ovarian cancer cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342776A (en) 1979-11-05 1982-08-03 Merck & Co., Inc. 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4399276A (en) 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS5839685A (ja) 1981-09-04 1983-03-08 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体及びその製造法
JPS58154582A (ja) 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US5004758A (en) 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
DK0418099T3 (da) 1989-09-15 2002-04-02 Res Triangle Inst Fremgangsmåde til fremstilling af 10,11-methylendioxy-20(RS)-camptothecin og 10,11-methylendioxy-20(S)-camptothecinanaloger
ATE247471T1 (de) * 1991-11-15 2003-09-15 Smithkline Beecham Corp Cisplatin und topotecan enthaltende zusammensetzung als antitumor.

Also Published As

Publication number Publication date
PT101061B (pt) 1999-07-30
EP0612248B1 (en) 2003-08-20
CA2123321C (en) 2003-09-30
EP1393730A3 (en) 2004-03-17
US5633016A (en) 1997-05-27
JPH07501079A (ja) 1995-02-02
EP0612248A4 (en) 1996-05-08
EP1393729A2 (en) 2004-03-03
ATE247471T1 (de) 2003-09-15
ES2204894T3 (es) 2004-05-01
ZA928771B (en) 1993-09-08
EP0612248A1 (en) 1994-08-31
EP1393730A2 (en) 2004-03-03
DE69233169D1 (de) 2003-09-25
HK1012268A1 (en) 1999-07-30
DE69233169T2 (de) 2004-05-27
NZ245112A (en) 1995-07-26
WO1993009782A1 (en) 1993-05-27
EP1393729A3 (en) 2004-03-17
DK0612248T3 (da) 2003-12-08
MX9206577A (es) 1993-05-01
AU3137993A (en) 1993-06-15
AU671605B2 (en) 1996-09-05
CA2123321A1 (en) 1993-05-27

Similar Documents

Publication Publication Date Title
PT101061A (pt) Composicoes farmaceuticas contendo anagolos da camptotecina e um composto de coordenacao de platina e seu uso na inibicao do crescimento de celulas tumorais
LV5503A3 (lv) Panemiens omeprazola salu iegusanai
EG17753A (en) Novel pharmacological compounds
MX163955B (es) Composicion farmaceutica de dihidrocodeina e ibuprofen
IL93360A (en) Bactericidal/permeability increasing protein or biologically active analogs thereof and pharmaceutical compositions containing them
MY101784A (en) Novel pharmacological compounds
CA2068324A1 (en) Metal-peptide compositions and methods for stimulating hair growth
IE862554L (en) Pharmaceutical compositions
HUT48458A (en) Composition for promoting dosage of pharmaceutical compositions
DE59410151D1 (de) Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
EP0137543A3 (en) Pharmaceutical composition for the therapy of peripheral arteriopathies
IL97251A0 (en) Antihypercholesterolemic 2,8-dioxabicyclo(3,2,1)octane derivatives,their preparation and pharmaceutical compositions containing them
DE3474774D1 (en) Therapeutic compositions for oral use containing stable s-adenosy1-l-methionine salts
IL95875A0 (en) Illudin analogs,pharmaceutical compositions containing the same and methods for the use thereof
EP0542860A4 (en) Immunosuppressive compositions
UA41285C2 (uk) Креатин фосфат і його фармацевтично прийнятні солі для лікування пухлин та фармацевтична композиція, що має протипухлинну активність
SE8600658D0 (sv) Novel composition of matter
LTIP1736A (en) Derivatives of human bile-salt stimulated lipase, and pharmaceutical compositions containing them
IT1240683B (it) Composizione farmaceutica contenente egf
PT100155A (pt) Uso de compostos analogos da camptotecina na obtencao de um medicamento para uso no tratamento do carcinoma das celulas nao pequenas do pulmao e composicoes farmaceuticas
ES8704903A1 (es) Un metodo para preparar 6-cloro-2-metil-1h-2,3,4,5-tetrahidro-3-benzazepen-n-oxido.
PT100156A (pt) Uso de compostos analogos da camptotecina na obtencao de um medicamento para uso no tratamento do cancro do ovario e composicoes farmaceuticas
DE3777411D1 (de) Mittel zur verbesserung der perkutanen verabreichung von arzneimitteln.
IL79207A0 (en) Pharmaceutical compositions containing terguide
JO1519B1 (en) New compounds (new benzimidazole derivatives are effective as ulcers)

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19931122

FG3A Patent granted, date of granting

Effective date: 19990420

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20121022